Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy.
Standard
Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. / Kröger, N; Hoffknecht, M; Dreger, P; Krüger, W; Zeller, W; Krüll, Andreas; Stockschläder, M; Bittner, S; Weh, H J; Zander, A R.
In: BONE MARROW TRANSPL, Vol. 21, No. 1, 1, 1998, p. 55-57.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy.
AU - Kröger, N
AU - Hoffknecht, M
AU - Dreger, P
AU - Krüger, W
AU - Zeller, W
AU - Krüll, Andreas
AU - Stockschläder, M
AU - Bittner, S
AU - Weh, H J
AU - Zander, A R
PY - 1998
Y1 - 1998
N2 - In advanced stage mantle cell lymphoma, conventional chemotherapy yields a complete remission rate below 40%, and the median survival rate is only about 3 years. Between 1991 and 1996 we treated nine such patients (six male; three female) with high-dose chemotherapy (six of these also with 12 Gy fractionated total body irradiation (TBI)) and peripheral stem cell support (n = 8) or allogeneic bone marrow transplantation (n = 1). The median age was 47 years (range, 28-61). At the time of high-dose chemotherapy, five patients were in first complete remission (CR), two in first partial remission (PR) and two in second remission (CR = 1; PR = 1). High-dose chemotherapy included TBI (12 Gy), etoposide and cyclophosphamide (patients 1-5), TBI and cyclophosphamide (patient 7), busulfan, etoposide and cyclophosphamide (patients 6 and 9), cyclophosphamide and busulfan (patient 8). The patterns of toxicity according to the Bearman score were usually mild (mucositis grade 2, n = 7; renal grade I, n = 2) with no therapy-related fatality. Only one patient developed hepatic toxicity grade III (veno-occlusive disease) but recovered completely. The median time to neutrophil engraftment was 10 days (range, 8-15). After high-dose chemotherapy all patients achieved complete remission. After a median follow-up of 22 months (range, 9.4-64) all patients remain in continuous complete remission. These encouraging results suggest that high-dose chemotherapy can be applied safely and leads to long-term disease-free survival in otherwise incurable disease.
AB - In advanced stage mantle cell lymphoma, conventional chemotherapy yields a complete remission rate below 40%, and the median survival rate is only about 3 years. Between 1991 and 1996 we treated nine such patients (six male; three female) with high-dose chemotherapy (six of these also with 12 Gy fractionated total body irradiation (TBI)) and peripheral stem cell support (n = 8) or allogeneic bone marrow transplantation (n = 1). The median age was 47 years (range, 28-61). At the time of high-dose chemotherapy, five patients were in first complete remission (CR), two in first partial remission (PR) and two in second remission (CR = 1; PR = 1). High-dose chemotherapy included TBI (12 Gy), etoposide and cyclophosphamide (patients 1-5), TBI and cyclophosphamide (patient 7), busulfan, etoposide and cyclophosphamide (patients 6 and 9), cyclophosphamide and busulfan (patient 8). The patterns of toxicity according to the Bearman score were usually mild (mucositis grade 2, n = 7; renal grade I, n = 2) with no therapy-related fatality. Only one patient developed hepatic toxicity grade III (veno-occlusive disease) but recovered completely. The median time to neutrophil engraftment was 10 days (range, 8-15). After high-dose chemotherapy all patients achieved complete remission. After a median follow-up of 22 months (range, 9.4-64) all patients remain in continuous complete remission. These encouraging results suggest that high-dose chemotherapy can be applied safely and leads to long-term disease-free survival in otherwise incurable disease.
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Disease-Free Survival
KW - Hematopoietic Stem Cell Transplantation
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Lymphoma, Non-Hodgkin/drug therapy/mortality
KW - Whole-Body Irradiation
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Disease-Free Survival
KW - Hematopoietic Stem Cell Transplantation
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Lymphoma, Non-Hodgkin/drug therapy/mortality
KW - Whole-Body Irradiation
M3 - SCORING: Journal article
VL - 21
SP - 55
EP - 57
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 1
M1 - 1
ER -
